FAQ: The Medicare GLP-1 Bridge Program

Despite reshaping obesity treatment, GLP-1 receptor agonists have remained out of reach for Medicare Part D beneficiaries seeking coverage for weight loss. Federal law prohibits Medicare from covering drugs solely for weight loss, meaning GLP-1s are only reimbursed under Part D for other approved indications, like type 2 diabetes, cardiovascular risk reduction, MASH, or sleep apnea.¹ Despite these constraints, the commercial consequence has been significant: Medicare logged $27.5 billion in gross GLP-1 spending across 21.8 million claims in 2024, entirely under FDA-approved indications other than obesity.¹ A new CMS demonstration is now attempting to expand that eligibility, at least temporarily.

What Is the Medicare GLP-1 Bridge and Why Does It Exist?

The Medicare GLP-1 Bridge is a short-term CMS demonstration providing eligible Part D beneficiaries with access to certain GLP-1 drugs for obesity at a flat $50 monthly copay, running July 1, 2026 through December 31, 2027.² Because current statute bars Part D from covering drugs used solely for weight loss, CMS cannot add GLP-1s to formularies directly; instead, the agency is acting under Section 402 demonstration authority, which permits time-limited testing of "changes in methods of payment or reimbursement.”² The program was also designed to collect GLP-1 utilization data to share with Part D plan sponsors ahead of potential implementation of the longer-term BALANCE Model.²

What Does the Bridge Mean for Patient Access — and What Are Its Limits?

The Bridge expands GLP-1 access for a Medicare population that has been categorically locked out of obesity coverage, and the $50 monthly copay represents a substantial reduction from higher cash-pay prices for branded agents. For eligible beneficiaries who clear the clinical and plan-type criteria, the demonstration reduces a significant financial barrier to initiating therapy. But the access picture is narrower than the headline suggests. Clinical thresholds, plan-type exclusions, a covered product list limited to three branded drugs, and the LIS cost-sharing carveout all constrain who can actually benefit. The Bridge also runs through December 31, 2027, and with the BALANCE Model indefinitely delayed, there is no guaranteed coverage pathway inside the program when the demonstration ends.

Which Drugs Are Covered Under the Bridge?

Three branded products are available when prescribed for weight reduction: Foundayo (all formulations), Wegovy (all formulations, including the oral tablet), and the Zepbound KwikPen.² Foundayo was added to the covered list on April 6, 2026, following FDA approval, and CMS has indicated the list could be updated further during the demonstration period.² GLP-1s prescribed for indications already covered under Part D are ineligible for the Bridge program; those beneficiaries continue accessing their medication through their Part D plan even if they would otherwise meet the clinical criteria.²

Who Is Eligible to Participate?

The program is available nationwide across all states and territories, but access is not universal, eligible beneficiaries must clear three bars: enrollment in a qualifying Part D plan type, use of a covered GLP-1 specifically for weight reduction and maintenance, and satisfaction of the Bridge's clinical criteria.² Beneficiaries must hold a standalone PDP or an MA-PD coordinated care plan for CY 2026; Special Needs Plans, employer/union group waiver plans, and LI NET enrollees are also eligible.² Beneficiaries in private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans are excluded unless they also carry a standalone PDP, and dually eligible beneficiaries in any qualifying plan type may participate provided they meet the clinical criteria.²

What Are the Payment Mechanics for Pharmacies?

Pharmacies collect a $50 copay from the beneficiary and submit claims electronically via the NCPDP Telecommunication Standard to a dedicated BIN/PCN, not to the beneficiary's Part D plan, with reimbursement set at wholesale acquisition cost minus the copay, plus a dispensing fee and applicable sales tax.² Humana will serve as the central processor for prior authorization, claims adjudication, and pharmacy payment nationwide, leveraging its existing infrastructure as administrator of the LI NET program.²

How Does the Bridge Sit Outside the Part D Benefit — and Why Does That Matter?

Because the Bridge operates entirely outside the standard Part D payment flow, Part D sponsors carry no financial risk and do not need to opt in — but the structural separation carries downstream implications for the entire supply chain.² Neither the $50 copay nor the drug cost counts toward a beneficiary's TrOOP accumulator under their Part D plan, and the $50 copay remains flat regardless of which phase of the Part D benefit the beneficiary is in when they fill a prescription — low-income subsidy cost-sharing does not apply, meaning LIS beneficiaries accustomed to reduced cost-sharing face the full $50 copay. Manufacturer coupons and discount programs cannot be applied at the point of claim for Bridge fills; manufacturer patient assistance programs, where available and where a beneficiary may qualify, operate outside and separate from the Bridge transaction entirely.²

What Are the Implications for the GLP-1 Market?

The Bridge is narrower than it may appear: it covers only weight management indications, excludes several plan types, currently limits the covered product list at three branded drugs, and compresses manufacturer net revenue to $245 per monthly supply while blocking copay offset programs.^1,2 The BALANCE Model's indefinite delay in Medicare Part D leaves manufacturers without a clear pathway to permanent formulary-based obesity coverage in the program, and the Medicaid picture is deteriorating rather than improving — state coverage fell from 16 states in 2025 to 13 states as of January 2026, a trend tied to budget pressures and federal funding reductions.¹ The Bridge generates utilization data and momentum, but it does not resolve the structural coverage question the industry is ultimately watching.

References

1. KFF, "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge," May 11, 2026 https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
2. CMS, Medicare GLP-1 Bridge, cms.gov (updated May 6, 2026) https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge